| Co-Investigator(Kenkyū-buntansha) |
MINAMINO Naoto National Cardiovascular Center Research Institute, Dept. of Pharmacol., Director, 薬理部, 部長 (50124839)
NAKAO Kazuwa Kyoto Univ., Graduate School of Med., Professor, 医学研究科, 教授 (00172263)
FUJITA Toshiro Univ. of Tokyo, School of Medicine, Professor, 医学部附属病院, 教授 (10114125)
KITAMURA Kazuo Miyazaki Medical College, 1st Dept Intern Med, Lecturer, 医学部, 講師 (50204912)
KANGAWA Kenji 宮崎医科大学, 生化学部, 部長 (00112417)
|
|---|
| Research Abstract |
"Adrenomedullin (AM)"is a novel hyportensive peptide which was discovered in human pheochromocytoma by monitoring the elevating activity of platelet cAMP. In addition, a novel 20 residues hypotensive peptide, termed "proadrenomedullin N-terminal 20 peptide" (PAMP), is processed from proadrenomedullin. AM and PAMP are widely biosynthesized in several tissues including heart, lung, aorta and kidney as well as in adrenal medulla. Both AM and PAMP show hypotensive effects in anesthetized rats, but exhibit different hypertensive mechanism. In this research, we have clarified the novel system for circulation control by AM and reralted peptides in the physiological and pathophysiological conditions. Adrenomedullin has been recognized as a true multi-functional peptide involved in regulating circulation, growth, neurotransmission, inflammation, and many others. The creation of a knockout mouse for adrenomedullin resulted in embryonic lethality, indicating clearly that adrenomedullin plays a major role in mammalian development. Further we are now applying the clinical implication for adrenomedullin in cardiovascular disorders. During these 5 years we have published more than 200 articles concerning adrenomedullin and PAMP. We believe that adrenomedullin will be a new therapeutic and diagnostic application for cardiovascular disorders in near future.
|
